Accordingly, early/low-risk MDS patients (RA and low-risk IPSS MDS) typically showed an overall increased proliferation of BM cells at the expenses of CD34+ non-lymphoid (myeloid plus uncommitted) precursors, maturing neutrophils and NRBC; conversely, advanced/high-risk patients showed progressive collapse of proliferation of these cell compartments, except for the more mature CD11b+ neutrophil-lineage cells, similarly to what was found in AML. The gene discussed is CD34; the disease is myelodysplastic syndrome.